Author | Everett E. Vokes, MD

Articles

Treatment of Advanced Head and Neck Cancer: Past, Present, and Future

September 01, 2008

ByVictoria M. Villaflor, MD|Everett E. Vokes, MD

Bruce Culliney and colleagues have provided a thorough and well written summary of the literature regarding multimodality treatment of patients with locoregionally advanced or unresectable head and neck malignancies. In particular, they offer a detailed outline of recent insights into radiation dosing and fractionation and their optimal use in the combined-modality setting.

Anti-EGFR Therapies: Clinical Experience in Colorectal, Lung, and Head and Neck Cancers

April 29, 2006

ByEverett E. Vokes, MD|Edward Chu, MD

Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types. While both inhibit the EGFR pathway, they act via different mechanisms.

Commentary (Brockstein/Vokes): Revisiting Induction Chemotherapy for Head and Neck Cancer

June 01, 2005

ByBruce Brockstein, MD|Everett E. Vokes, MD

Argiris et al present a comprehensivereview of inductionchemotherapy for head andneck cancer, and should be lauded fortheir meticulous work. This papercarefully delineates and categorizesmost of the relevant induction chemotherapystudies in head and neckcancer performed over the past 3 decades.The authors have sought to answerquestions regarding the optimalnumber of chemotherapy cycles (acritical factor when one uses responseto induction chemotherapy to determineeligibility for organ preservationor in an attempt to enhance curerates), the optimal chemotherapyregimen, and the possibility of a sitespecificbenefit to induction chemotherapy.The paper assesses benefitbased on treatment intent-that is, organpreservation vs survival benefit.Importantly, by excavating the layersof the past, the authors provide aframework with which to construct anew paradigm of treatment for headand neck cancer that may again incorporateinduction chemotherapy.

Commentary (Cohen/Vokes): Gene Therapy for Head and Neck Cancers

March 01, 2001

ByEzra E. W. Cohen, MD|Everett E. Vokes, MD

This issue of Oncology features an excellent review of gene therapy for head and neck cancers. Lamont and colleagues have highlighted the principles of genetic intervention, the current state of available therapies, and the results of human trials in an organized and coherent manner.